373 related articles for article (PubMed ID: 25586216)
1. Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.
Tun GS; Lobo AJ
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):317-27. PubMed ID: 25586216
[TBL] [Abstract][Full Text] [Related]
2. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
Smith LS; Nelson M; Dolder CR
Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
[TBL] [Abstract][Full Text] [Related]
3. Certolizumab pegol for the management of Crohn's disease in adults.
Rivkin A
Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
[TBL] [Abstract][Full Text] [Related]
4. Certolizumab pegol in the treatment of Crohn's disease.
Ferrante M; Vermeire S; Rutgeerts P
Expert Opin Biol Ther; 2013 Apr; 13(4):595-605. PubMed ID: 23451881
[TBL] [Abstract][Full Text] [Related]
5. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
[TBL] [Abstract][Full Text] [Related]
6. Maintenance therapy with certolizumab pegol for Crohn's disease.
Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
[TBL] [Abstract][Full Text] [Related]
7. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.
Pasut G
BioDrugs; 2014 Apr; 28 Suppl 1():S15-23. PubMed ID: 24687235
[TBL] [Abstract][Full Text] [Related]
8. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.
Colombel JF; Sandborn WJ; Allez M; Dupas JL; Dewit O; D'Haens G; Bouhnik Y; Parker G; Pierre-Louis B; Hébuterne X
Clin Gastroenterol Hepatol; 2014 Mar; 12(3):423-31.e1. PubMed ID: 24184736
[TBL] [Abstract][Full Text] [Related]
9. Drug safety evaluation of certolizumab pegol.
Ferrante M; Vermeire S; Rutgeerts PJ
Expert Opin Drug Saf; 2014 Feb; 13(2):255-66. PubMed ID: 24156537
[TBL] [Abstract][Full Text] [Related]
10. Certolizumab pegol for the treatment of Crohn's disease.
Sandborn WJ; Feagan BG; Stoinov S; Honiball PJ; Rutgeerts P; Mason D; Bloomfield R; Schreiber S;
N Engl J Med; 2007 Jul; 357(3):228-38. PubMed ID: 17634458
[TBL] [Abstract][Full Text] [Related]
11. Certolizumab pegol in Crohn's disease.
Patel VK; Ghosh S
Drugs Today (Barc); 2008 Nov; 44(11):837-44. PubMed ID: 19180261
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease.
Shao LM; Chen MY; Cai JT
Aliment Pharmacol Ther; 2009 Mar; 29(6):605-14. PubMed ID: 19183161
[TBL] [Abstract][Full Text] [Related]
14. A review and expert opinion of the use of certolizumab for Crohn's disease.
Evans AT; Lee SD
Expert Opin Biol Ther; 2012 Mar; 12(3):363-70. PubMed ID: 22339409
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease.
Hanauer SB; Panes J; Colombel JF; Bloomfield R; Schreiber S; Sandborn WJ
Aliment Pharmacol Ther; 2010 Aug; 32(3):384-93. PubMed ID: 20491747
[TBL] [Abstract][Full Text] [Related]
16. Certolizumab pegol: a polyethylene glycolated Fab' fragment of humanized anti-tumor necrosis factor alpha monoclonal antibody for the treatment of Crohn's disease.
Baker DE
Rev Gastroenterol Disord; 2008; 8(4):240-53. PubMed ID: 19107098
[TBL] [Abstract][Full Text] [Related]
17. Profile of certolizumab and its potential in the treatment of psoriatic arthritis.
Chimenti MS; Saraceno R; Chiricozzi A; Giunta A; Chimenti S; Perricone R
Drug Des Devel Ther; 2013; 7():339-48. PubMed ID: 23620660
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey.
Vavricka SR; Schoepfer AM; Bansky G; Binek J; Felley C; Geyer M; Manz M; Rogler G; de Saussure P; Sauter B; Scharl M; Seibold F; Straumann A; Michetti P;
Inflamm Bowel Dis; 2011 Jul; 17(7):1530-9. PubMed ID: 21674709
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.
Schoepfer AM; Vavricka SR; Binek J; Felley C; Geyer M; Manz M; Rogler G; de Saussure P; Sauter B; Seibold F; Straumann A; Michetti P;
Inflamm Bowel Dis; 2010 Jun; 16(6):933-8. PubMed ID: 20014021
[TBL] [Abstract][Full Text] [Related]
20. Certolizumab pegol: in Crohn's disease.
Blick SK; Curran MP
BioDrugs; 2007; 21(3):195-201; discussion 202-3. PubMed ID: 17516714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]